The questions healthcare teams actually ask.

We typically start with a one-to-two month test window and a media budget large enough to produce a useful read on qualification and downstream economics. The right threshold depends on the patient journey, geography, conversion rate, and value of the downstream outcome. We'll tell you honestly on the first call if the available volume or budget is too small to learn anything.

Yes. Clinical-trial recruitment is one of our specialties, so we can work with sponsors, CROs, site networks, or sites where the operating model makes sense. Across healthcare more broadly, the important question is the same: can the engagement give us enough downstream outcome data to judge acquisition on more than lead volume?

The patient journey, serviceable geographies, downstream outcome you care about, operating constraints, and acquisition budget are enough to start. Prior channel or funnel performance helps. For clinical-trial recruitment, we will also need the relevant protocol criteria, enrollment target, site model, and approval process.

We recommend cutting it. Every channel is launched with an economic threshold agreed up front, which makes that call a documented decision rather than an argument. We would rather concentrate budget in the channels that work than defend a broad media mix for its own sake.

Operational capacity is a constraint we design around, not an afterthought. We agree what a useful handoff looks like, avoid sending demand the operation cannot realistically serve, and ask for downstream dispositions in whatever format is workable. If acquisition is creating avoidable operational waste, we treat that as part of the acquisition problem.

Enrollment economics. Cost per lead is a checkpoint, not the goal. In clinical-trial recruitment we reconcile screening and enrollment outcomes back to source; in other healthcare models the equivalent may be a qualified patient, booked visit, completed consultation, treatment start, or another downstream outcome that actually determines the economics.

Through whatever approved system can provide it — EHR or CRM exports, booking status, CTMS data, referral outcomes, call-center dispositions, or even a simple weekly reconciliation. We use the lightest-weight pipeline that still lets acquisition decisions reflect real downstream outcomes.

A standing weekly view of spend, qualification, and the early downstream signals available by channel and campaign, plus a deeper periodic review that reconciles against business or clinical outcomes. Reporting should use the terms your operation already uses rather than forcing the business to translate an ad-platform dashboard.

We recommend cutting it. Every channel is launched with an economic threshold agreed up front, which makes that call a documented decision rather than an argument. We would rather concentrate budget in the channels that work than defend a broad media mix for its own sake.

Through whatever approved system can provide it — EHR or CRM exports, booking status, CTMS data, referral outcomes, call-center dispositions, or even a simple weekly reconciliation. We use the lightest-weight pipeline that still lets acquisition decisions reflect real downstream outcomes.

We don't sell guaranteed volume, because inflating volume is often what erodes quality. What we commit to is a qualification and routing framework built around the patient journey, plus transparent downstream reporting so you can see whether quality is improving or deteriorating.

We identify the constraints that create obvious mismatches and handle them as early as the acquisition model responsibly allows. In clinical-trial recruitment that can mean protocol-based pre-screening before a referral reaches a coordinator. In virtual care it may mean geography, coverage, service availability, or another intake constraint.

Operational capacity is a constraint we design around, not an afterthought. We agree what a useful handoff looks like, avoid sending demand the operation cannot realistically serve, and ask for downstream dispositions in whatever format is workable. If acquisition is creating avoidable operational waste, we treat that as part of the acquisition problem.

Our core strength is performance marketing — paid social, search, and programmatic — combined with qualification and downstream measurement. Our current specialty positioning includes clinical-trial recruitment and virtual care. The model travels across therapeutic areas because the discipline is the same: buy on unit economics, screen hard, and optimize to the outcome that actually funds the program.

Yes, and we plan for it from the first test rather than discovering it later. Creative concepts are drafted to fit the language and materials your IRB or ethics-review process requires, submissions are batched so approval is not a per-asset bottleneck, and the test matrix is built to still be readable within the set of variants you are permitted to run.

We identify the constraints that create obvious mismatches and handle them as early as the acquisition model responsibly allows. In clinical-trial recruitment that can mean protocol-based pre-screening before a referral reaches a coordinator. In virtual care it may mean geography, coverage, service availability, or another intake constraint.

We design measurement so patient-level health information stays in the approved intake, EHR, CRM, CTMS, or clinical system rather than being disclosed to an ad platform. Downstream outcomes can still be reconciled to source for reporting and media decisions using the minimum data necessary and an agreed workflow. Any platform-side conversion signal is limited to data permitted by that platform's terms and the applicable privacy framework. Where we handle PHI on behalf of a HIPAA-regulated client, the required BAA and data-handling controls are agreed before launch.

Yes, and we plan for it from the first test rather than discovering it later. Creative concepts are drafted to fit the language and materials your IRB or ethics-review process requires, submissions are batched so approval is not a per-asset bottleneck, and the test matrix is built to still be readable within the set of variants you are permitted to run.